Diagnostic, Prognostic, and Therapeutic Biomarkers for Ovarian Cancer
Submission Deadline: 15 Jun 2023
Guest Editors
Department of Obstetrics and Gynecology, the First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Interests: ovarian cancer
Special Issue in IMR Press journals
Special Issue in Advances in Diagnosis and Treatment of Epithelial Ovarian Cancer
Department of Gynecology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Interests: ovarian cancer
Special Issue Information
Dear Colleagues,
Despite the development of several treatment options, ovarian cancer remains a major cause of death for women worldwide. Early diagnosis is one of the most important factors that determine survival from ovarian cancer. However, current clinical diagnostic tools have limited efficacy for the early detection of this cancer type, hence there is an urgent need for new diagnostic biomarkers. Advances in knowledge acquired from genomic, metabolomic and proteomic techniques should lead to the discovery of novel biomarkers with clinical utility for the diagnosis, prognostic assessment, and therapeutic evaluation of ovarian cancer. Specific diagnostic biomarkers may therefore have profound diagnostic, prognostic and therapeutic implications for ovarian cancer.
Dr. Juan Zhou
Guest Editor
Keywords
- ovarian cancer
- biomarkers
- treatment
- prognosis
Manuscript Submission Information
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted manuscripts should be well formatted in good English.
Published Papers (4)
LncRNA PART1 Regulates Ovarian Carcinoma Development via the miR-150-5p/MYB Axis
Front. Biosci. (Landmark Ed) 2023, 28(10), 270; https://doi.org/10.31083/j.fbl2810270
(This article belongs to the Special Issue Diagnostic, Prognostic, and Therapeutic Biomarkers for Ovarian Cancer)
NOTCH Pathway Genes in Ovarian Cancer: Clinical Significance and Associations with Immune Cell Infiltration
Front. Biosci. (Landmark Ed) 2023, 28(9), 220; https://doi.org/10.31083/j.fbl2809220
(This article belongs to the Special Issue Diagnostic, Prognostic, and Therapeutic Biomarkers for Ovarian Cancer)
N6-methyladenosine Methyltransferase METTL3 Enhances PTGER2 Expression to Increase Ovarian Cancer Stemness and Chemoresistance
Front. Biosci. (Landmark Ed) 2023, 28(9), 199; https://doi.org/10.31083/j.fbl2809199
(This article belongs to the Special Issue Diagnostic, Prognostic, and Therapeutic Biomarkers for Ovarian Cancer)
A Comprehensive Analysis of Prognostic Indicators in Serous Ovarian Cancer Based on Leukocyte Migration and Immune Microenvironment
Front. Biosci. (Landmark Ed) 2023, 28(6), 130; https://doi.org/10.31083/j.fbl2806130
(This article belongs to the Special Issue Diagnostic, Prognostic, and Therapeutic Biomarkers for Ovarian Cancer)